Výsledky vyhledávání

Akademický článek

Trends in antineoplastic drug use, cost and prescribing patterns among patients with lung cancer in nine major cities of China, 2016–2020: a retrospective observational study based on inpatient and outpatient hospital data

Autor: Yi Liu, Lixin Zhou, Xiaohong Zhang, Feng Yang, Rongrong Fan, Jingyuan Shang, Lin Huang, Yanguo Liu, Chunyan Zhang, Li'an Zu, Yufei Feng

Publikováno v: BMJ Open, Vol 13, Iss 3 (2023)

Objectives It is unclear whether the use of antineoplastic drugs for patients with lung cancer in China has changed after the implementation of the national drug price negotiation in 2016 and continual update of clinical guidelines. This study aims t

Externí odkaz: https://doaj.org/article/7b2f8413a92141228fb2aae136c07c3a

Zobrazit plný text záznamu

Akademický článek

Safety and tolerability of a single dose T0001 in Chinese healthy adult volunteers: a first-in-human ascending dose study

Autor: Tan Zhang, Minjie Zhang, Li’an Zu, Qian Wang, Qi Wang, Wei Wang, Yitong Wang, Yannan Zang, Zhenwei Xie, Shi Chen, Mei Wang, Qingshan Zheng, Zhanguo Li, Guihong Chen, Yi Fang

Publikováno v: Brazilian Journal of Pharmaceutical Sciences, Vol 56 (2020)

T0001 is the first mutant of etanercept with a higher affinity to tumor necrosis factor α (TNF-α) than etanercept. In order to investigate the safety and tolerability of T0001, a study was carried out in healthy Chinese subjects. A first-in-human,

Externí odkaz: https://doaj.org/article/65c7f4c101314d34b9ed72e2da5438a8

Zobrazit plný text záznamu

Autor: Jingyuan Shang, Lixin Zhou, Lin Huang, Feng Yang, Yanguo Liu, Chunyan Zhang, Li'an Zu, Rongrong Fan, Xiaohong Zhang, Yi Liu, Yufei Feng

Publikováno v: BMJ Open. 13:e069645

ObjectivesIt is unclear whether the use of antineoplastic drugs for patients with lung cancer in China has changed after the implementation of the national drug price negotiation in 2016 and continual update of clinical guidelines. This study aims to

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::981c60edb5cfc6f8dd283b017b17d046
https://doi.org/10.1136/bmjopen-2022-069645

Zobrazit plný text záznamu

Akademický článek

Gut microbiota and metabolomic profile changes play critical roles in tacrolimus-induced diabetes in rats

Autor: Zhenwei Jiang, Minyan Qian, Zeng Zhen, Xuping Yang, Caomei Xu, Li’an Zuo, Jingting Jiang, Wenting Zhang, Nan Hu

Publikováno v: Frontiers in Cellular and Infection Microbiology, Vol 14 (2024)

AimsHyperglycemia is one of the adverse effects of tacrolimus (TAC), but the underlying mechanism is not fully identified. We used multi-omics analysis to evaluate the changes in the gut microbiota and metabolic profile of rats with TAC-induced diabe

Externí odkaz: https://doaj.org/article/08977502bc6d44dd8ea735309d857e9b

Zobrazit plný text záznamu

Safety and tolerability of a single dose T0001 in Chinese healthy adult volunteers: a first-in-human ascending dose study

Autor: Qingshan Zheng, Minjie Zhang, Yi Fang, Tan Zhang, Wei Wang, Yannan Zang, Guihong Chen, Zhanguo Li, Qian Wang, Shi Chen, Mei Wang, Yitong Wang, Qi Wang, Li’an Zu, Zhenwei Xie

Publikováno v: Brazilian Journal of Pharmaceutical Sciences, Vol 56 (2020)
Brazilian Journal of Pharmaceutical Sciences, Volume: 56, Article number: e18447, Published: 07 DEC 2020
Brazilian Journal of Pharmaceutical Sciences; Vol. 56 (2020); e18447
Brazilian Journal of Pharmaceutical Sciences; v. 56 (2020); e18447
Brazilian Journal of Pharmaceutical Sciences
Universidade de São Paulo (USP)
instacron:USP

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::33b2d744d1cf7261595bb875081d324c
http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1984-82502020000100598&tlng=en

Zobrazit plný text záznamu

A Phase I Study Comparing the Pharmacokinetics, Safety, and Immunogenicity of Proposed Biosimilar GB242 and Reference Infliximab in Healthy Subjects

Autor: Guihong Chen, Haifeng Song, Shengbin Ren, Youzhong An, Jie Lv, Yi Fang, Yitong Wang, Qi Wang, Li’an Zu, Chang Liu, Tan Zhang, Qingshan Zheng, Qian Wang, Huiyang Cheng, Lihou Dong

Publikováno v: BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy. 33(1)

The objective of this study was to compare the pharmacokinetics (PKs), safety, and immunogenicity of GB242 as a potential biosimilar infliximab with those of reference infliximab in healthy Chinese subjects. We conducted a randomized, single-center,

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e18f651b66163c5c21f9ddc980534277
https://pubmed.ncbi.nlm.nih.gov/30511316

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání